Maquet buys LAA closure device developer

Candace Stuart | May 21, 2013 | Cardiovascular Business | Heart Rhythm

Maquet Cardiovascular has acquired LAAx, the developer of an implantable left atrial appendage (LAA) closure device.

LAAx makes the TigerPaw System II, a mechanical occlusion device that is indicated for the occlusion of the LAA under direct visualization, in conjunction with other open cardiac surgical procedures. The device is approved in the U.S. and the European Union, according Rastatt, Germany-based Maquet.

The implanted TigerPaw System II uses a single-use delivery tool and an implantable fastener to occlude the LAA during open chest procedures. “We believe TigerPaw II will be a best-in-class device for reliable ligation of the LAA, potentially mitigating post-operative stroke and its associated costs in patients with atrial fibrillation undergoing cardiac surgery,” Peter Hinchliffe, president and CEO for the Cardiac Surgery Business Unit of Maquet, said in a release.

LAAx is based in Livermore, Calif. Terms of the acquisition were not disclosed.

Candace Stuart, Contributor

Around the web

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Maquet buys LAA closure device developer

Related Content

Around the web